Filter posts

ICYMI: Making Biopharmaceutical Innovation a Priority of the Next Administration

Last week, Astellas Americas President Jim Robinson wrote an op-ed in Forbes exploring, “How The …

ICYMI: Peter Pitts Weighs in on Drug Price Debate

This week in the Sacramento Bee, Peter J. Pitts, a former U.S. Food and Drug …

High Tech Animals Stuck On the Shelf

David Warmflash writes for the Genetic Literacy Project about the challenges being faced by innovators …

BIO Principles Put Patients First

Patient advocacy organizations play an indispensable role in the biopharmaceutical development process: They help scientists …

WSJ: A Piece of the Immunotherapy Puzzle Solved

Just two weeks ago, the New York Times published a series of articles deeming immunotherapy …

What We're Reading at GMO Answers

Each month, GMO Answers compiles a few of our favorite news stories into one post …

The Washington Post Unfairly Attacks The Orphan Drug Act

The Orphan Drug Act has been a tremendous success and addressed a market failure by …

BIO Releases Points to Consider on Truthful and Non-Misleading Product Communication

Today, BIO releases Points to Consider on Truthful and Non-Misleading Product Communication. This document advances the dialogue …

ICYMI: NYT Chronicles Advances in Cancer Landscape Due to Immunotherapy

This week, the New York Times published a series of articles titled Cell Wars which explores …

Are GE Mosquitos REALLY Scarier Than the Non-Modified Disease-Carrying Kind?

Florida health officials and the Centers for Disease Control (CDC) announced last week that the …